These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 25035309)

  • 1. Non-cardiovascular effects associated with statins.
    Desai CS; Martin SS; Blumenthal RS
    BMJ; 2014 Jul; 349():g3743. PubMed ID: 25035309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SLCO1B1 variants and statin-induced myopathy--a genomewide study.
    ; Link E; Parish S; Armitage J; Bowman L; Heath S; Matsuda F; Gut I; Lathrop M; Collins R
    N Engl J Med; 2008 Aug; 359(8):789-99. PubMed ID: 18650507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population.
    Hubáček JA; Dlouhá D; Adámková V; Zlatohlavek L; Viklický O; Hrubá P; Češka R; Vrablík M
    Med Sci Monit; 2015 May; 21():1454-9. PubMed ID: 25992810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are statins really wonder drugs?
    Grover HS; Luthra S; Maroo S
    J Formos Med Assoc; 2014 Dec; 113(12):892-8. PubMed ID: 24231094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants.
    Yebyo HG; Aschmann HE; Kaufmann M; Puhan MA
    Am Heart J; 2019 Apr; 210():18-28. PubMed ID: 30716508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association.
    Newman CB; Preiss D; Tobert JA; Jacobson TA; Page RL; Goldstein LB; Chin C; Tannock LR; Miller M; Raghuveer G; Duell PB; Brinton EA; Pollak A; Braun LT; Welty FK;
    Arterioscler Thromb Vasc Biol; 2019 Feb; 39(2):e38-e81. PubMed ID: 30580575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.
    Wilke RA; Ramsey LB; Johnson SG; Maxwell WD; McLeod HL; Voora D; Krauss RM; Roden DM; Feng Q; Cooper-Dehoff RM; Gong L; Klein TE; Wadelius M; Niemi M;
    Clin Pharmacol Ther; 2012 Jul; 92(1):112-7. PubMed ID: 22617227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of risk factors for statin-induced myopathy in rheumatoid arthritis patients.
    Toms TE; Smith JP; Panoulas VF; Douglas KM; Saratzis AN; Kitas GD
    Musculoskeletal Care; 2010 Mar; 8(1):2-9. PubMed ID: 19642078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of genetic factors in statins side-effects.
    Scarpini F; Cappellone R; Auteri A; Puccetti L
    Cardiovasc Hematol Disord Drug Targets; 2012 Sep; 12(1):35-43. PubMed ID: 22524173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink.
    Carr DF; O'Meara H; Jorgensen AL; Campbell J; Hobbs M; McCann G; van Staa T; Pirmohamed M
    Clin Pharmacol Ther; 2013 Dec; 94(6):695-701. PubMed ID: 23942138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse effects of statins - myths and reality.
    Šimić I; Reiner Ž
    Curr Pharm Des; 2015; 21(9):1220-6. PubMed ID: 25312733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.
    Brunham LR; Lansberg PJ; Zhang L; Miao F; Carter C; Hovingh GK; Visscher H; Jukema JW; Stalenhoef AF; Ross CJ; Carleton BC; Kastelein JJ; Hayden MR
    Pharmacogenomics J; 2012 Jun; 12(3):233-7. PubMed ID: 21243006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review.
    Canestaro WJ; Austin MA; Thummel KE
    Genet Med; 2014 Nov; 16(11):810-9. PubMed ID: 24810685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice.
    Bruckert E; Ferrières J
    Arch Cardiovasc Dis; 2014 Mar; 107(3):188-200. PubMed ID: 24613429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statin-induced myopathies.
    Tomaszewski M; Stępień KM; Tomaszewska J; Czuczwar SJ
    Pharmacol Rep; 2011; 63(4):859-66. PubMed ID: 22001973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SLCO1B1 variants and statin-induced myopathy.
    Vladutiu GD; Isackson PJ
    N Engl J Med; 2009 Jan; 360(3):304. PubMed ID: 19144951
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacogenomics of statin therapy: any new insights in efficacy or safety?
    Hopewell JC; Reith C; Armitage J
    Curr Opin Lipidol; 2014 Dec; 25(6):438-45. PubMed ID: 25313593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addressing statin adverse effects in the clinic: the 5 Ms.
    Katz DH; Intwala SS; Stone NJ
    J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):533-42. PubMed ID: 24770611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Researchers worry about myopathy risk for patients taking high-dose simvastatin.
    Mitka M
    JAMA; 2009 Jan; 301(3):261-2. PubMed ID: 19155447
    [No Abstract]   [Full Text] [Related]  

  • 20. Statin safety: a systematic review.
    Law M; Rudnicka AR
    Am J Cardiol; 2006 Apr; 97(8A):52C-60C. PubMed ID: 16581329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.